Should weight loss be recommended in patients with end-stage organ failure who are overweight or obese despite their compromised medical condition? Why or why not?   How do you balance the potential...

Should weight loss be recommended in patients with end-stage organ failure who are overweight or obese despite their compromised medical condition? Why or why not?

How do you balance the potential risks of administering EN with the outcome benefits of using EN in the HSCT population?

What parameters would you use in determining the suitability of and to monitor tolerance to EN?

Would you recommend using EN in clinical practice when caring for your HSCT patient?